Effects of AT1- and β-adrenergic receptor antagonists on TGF-β1-induced fibrosis in transgenic mice

European Journal of Clinical Investigation

Volumn 39, Issue 10, 2009, Pages 851-859

  Seeland, U ^a   Schaffer A ^a   Selejan, S ^a   Hohl, M ^a   Reil, J C ^a   Muller P ^a   Rosenkranz, S ^b   Bohm M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cardiac remodelling; Hypertrophy; Interstitial remodelling; Transforming growth factor 1; Transgenic mouse model

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; COLLAGENASE; COLLAGENASE 3; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; METOPROLOL; TELMISARTAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOBLOTTING; INTERSTITIUM; MALE; MORPHOMETRICS; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ZYMOGRAPHY;

ANIMALS; BENZIMIDAZOLES; BENZOATES; CARDIOMYOPATHIES; COLLAGEN; METOPROLOL; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHENOTYPE; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70349251728     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02183.x     Document Type: Article

References (42)

1. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999 79 : 215 262. Review.
2. Böhm M, Kouchi I, Schnabel P, Zolk O. Transition from hypertrophy to failure -β-adrenergic desensitization of the heart. Heart Fail Rev 1999 4 : 329 351.
3. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor. Circ Res 1993 73 : 413 423.
4. Parker TG, Schneider MD. Growth factors, protooncogenes, and plasticity of the cardiac phenotype. Annu Rev Physiol 1991 53 : 179 200.
5. Sudgen PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998 76 : 725 746.
6. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R et al. Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003 278 : 12384 12389.
7. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-β1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995 27 : 2347 2357.
8. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997 29 : 1947 1958.
9. Kupfahl C, Pink D, Friedrich K, Zurbrügg HR, Neuss M, Warnecke C et al. Angiotensin II directly increases transforming growth factor-β1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 2000 46 : 463 475.
10. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 2002 91 : 1103 1113.
11. Heimer R, Bashey RI, Kyle J, Jimenez SA. TGF-β modulates the synthesis of proteoglycans by myocardial fibroblasts in culture. J Mol Cell Cardiol 1995 27 : 2191 2198.
12. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U et al. Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 2002 283 : H1253 62.
13. Schlüter KD, Zhou XJ, Piper HM. Induction of hypertrophic responsiveness to isoproterenol by TGF-β in adult rat cardiomyocytes. Am J Physiol Cell Physiol 1995 269 : C1311 6.
14. Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007 74 : 184 195.
15. Leask A. TGF-β, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007 74 : 207 212.
16. Villarreal FJ, Lee AA, Dillmann WH, Giordano FJ. Adenovirus-mediated overexpression of human transforming growth factor-β1 in rat cardiac fibroblasts, myocytes and smooth muscle cells. J Mol Cell Cardiol 1996 28 : 735 742.
17. Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K et al. Myocardial fibrosis in transforming growth factor-β1 (TGF-β1) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002 32 : 295 303.
18. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L et al. Hepatic expression of mature transforming growth factor-β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995 92 : 2572 2576.
19. Lowry OH, Rosebrough NJ. Protein measurement. J Biol Chem 1951 193 : 265 275.
20. Seeland U, Selejan S, Engelhardt S, Müller P, Lohse MJ, Böhm M. Interstitial remodeling in β1-adrenergic receptor transgenic mice. Basic Res Cardiol 2007 102 : 183 193.
21. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlöf B et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Circulation 2004 110 : 552 557.
22. Sadoshima J, Xu YH, Slayter HS, Izumo S. Autocrine release of angiotensin-II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993 75 : 977 984.
23. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol 2004 43 : 2200 2206.
24. Rosenkranz S. TGF-β1 and angiotensin II networking in cardiac remodeling. Cardiovasc Res 2004 63 : 423 432.
25. Deten A, Holzl A, Leicht M, Barth W, Zimmer HG. Changes in extracellular matrix and in transforming growth factor-β isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001 33 : 1191 1207.
26. Yu CM, Tipoe GL, Wing-Hon Lai K, Lau CP. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001 38 : 1207 1215.
27. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor β1 and repair in the infarcted heart. J Mol Cell Cardiol 1998 30 : 1559 1569.
28. Kimura M, Ogihara M. Transforming growth factor-β1 inhibits the growth of primary hepatocyte cultures by increasing cAMP levels. Eur J Pharmacol 1999 386 : 271 277.
29. Iizuka K, Sano H, Kawaguchi H, Kitabatake A. Transforming growth factor β1 modulates the number of β-adrenergic receptors in cardiac fibroblasts. J Mol Cell Cardiol 1994 26 : 435 440.
30. Fisher SA, Absher M. Norepinephrine and angiotensin II stimulate secretion of TGF-β by neonatal rat cardiac fibroblasts in vitro. Am J Physiol Cell Physiol 1995 268 : C910 7.
31. Schultz JJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002 109 : 787 796.
32. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 1995 27 : 2177 2189.
33. Balbin M, Fueyo A, Knäuper V, Lopez JM, Alvarez J, Sanchez LM et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001 276 : 10253 10262.
34. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study. Circulation 2007 116 : 700 705.
35. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-added trial. Lancet 2003 362 : 767 771.
36. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002 8 : 35 40.
37. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002 55 : 76 82.
38. Buchdunger E, Cioffi C, Law N, Stover D, Ohno-Jones S, Druker B et al. Abl protein-tyrosin kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 295 : 139 145.
39. Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M et al. Transforming growth factor-β activation of phosphatidylinositol-3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005 65 : 10431 10440.
40. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 105 : 2640 2653.
41. Leipner C, Grün K, Müller A, Buchdunger E, Borsi L, Kosmehl H et al. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. Cardiovasc Res 2008 79 : 118 126.
42. Wang S, Wilkes M, Leof E, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 2005 19 : 1 11.